CoChat

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Microvascular disease is associated with a high risk of macrovascular events in patients with type 2 diabetes, but the impact of macrovascular disease on the risk of microvascular events remains unknown. We sought to evaluate the respective effects of prior microvascular and macrovascular disease on the risk of major outcomes, including microvascular events, in these patients. METHODS: Participants in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) trial (n = 11,140) and the ADVANCE-ON post-trial study (n = 8494) were categorized into 4 groups at baseline: dual absence of microvascular or macrovascular disease (n = 6789), presence of microvascular disease alone (n = 761), macrovascular disease alone (n = 3196), and both (n = 394). Outcomes were all-cause mortality, major macrovascular events (MACE), and major clinical microvascular events. RESULTS: All-cause mortality, MACE, and major clinical microvascular events occurred in 2265 (20%), 2166 (19%), and 807 (7%) participants respectively, during a median follow-up of 9.9 (inter-quartile interval 5.6-10.9) years. The adjusted hazard ratios [95% CI] of death, MACE, and major clinical microvascular events were each greater in patients with baseline microvascular disease (1.43 [1.20-1.71], 1.64 [1.37-1.97], and 4.74 [3.86-5.82], respectively), macrovascular disease (1.43 [1.30-1.57], 2.04 [1.86-2.25], and 1.26 [1.06-1.51]) or both (2.01 [1.65-2.45], 2.92 [2.40-3.55], and 6.30 [4.93-8.06]) compared with those without these conditions. No interaction was observed between baseline microvascular and macrovascular disease for these events. The addition of microvascular disease (change in c-statistic [95% CI] 0.005 [0.002-0.008], p = 0.02) or macrovascular disease (0.005 [0.002-0.007], p < 0.0001) considered separately or together (0.011 [0.007-0.014], p < 0.0001) improved the discrimination and the classification (integrated discrimination improvement (IDI): 0.013 [0.010-0.016], p < 0.001; net reclassification improvement (NRI): 0.021 [0.011-0.032], p < 0.001) of the risk of all-cause mortality. Microvascular disease improved discrimination (0.009 [0.003-0.014]) and classification (IDI: 0.008 [0.006-0.010]; NRI: 0.011 [0.001-0.020]) of MACE. Baseline macrovascular disease modestly enhanced IDI (0.002 [0.001-0.002]) and NRI (0.041 [0.002-0.087]), but not discrimination, of major clinical microvascular events. CONCLUSIONS: Microvascular and macrovascular disease are independently associated with the 10-year risk of death, MACE, and major clinical microvascular events in patients with type 2 diabetes. The coexistence of these conditions was associated with the highest risks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-017-0574-y

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cumulative incidence of outcomes during follow-up according to status of microvascular and macrovascular disease at baseline. a All-cause mortality. b Major macrovascular events. c Major clinical microvascular disease (p < 0.0001 for all). Black line absence of both macrovascular and microvascular disease. Blue line presence of microvascular disease alone. Green line presence of macrovascular disease alone. Red line presence of both microvascular and macrovascular disease
Fig. 1 Cumulative incidence of outcomes during follow-up according to status of microvascular and macrovascular disease at baseline. a All-cause mortality. b Major macrovascular events. c Major clinical microvascular disease (p < 0.0001 for all). Black line absence of both macrovascular and microvascular disease. Blue line presence of microvascular disease alone. Green line presence of macrovascular disease alone. Red line presence of both microvascular and macrovascular diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 118

Metadata

Authors
Mohammedi, K., Woodward, M., Marre, M., Colagiuri, S., Cooper, M., Harrap, S., Mancia, G., Poulter, N., Williams, B., Zoungas, S., & Chalmers, J.
Affiliations
  • The University of Sydney (AU)
  • Inserm (FR)
  • Baker Heart and Diabetes Institute (AU)
  • The Royal Melbourne Hospital (AU)
  • IRCCS Istituto Auxologico Italiano (IT)
  • Imperial College London (GB)
  • National Institute for Health and Care Research (GB)
Corresponding author
Mohammedi, Kamel
Venue
Cardiovascular Diabetology
Published
2017-07-27
Volume
16
Issue
1
Pages
95-95
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2740555108
Cited by
111
References
36
Citations by year
2026: 7 · 2025: 12 · 2024: 10 · 2023: 5 · 2022: 23 · 2021: 16 · 2020: 10 · 2019: 7 · 2018: 13 · 2017: 8
FWCI
8.22
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Monash University Research Portal (Monash University) (submittedVersion, cc-by)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • National Institute for Health and Care Research (NF-SI-0509-10222, NF-SI-0514-10011)
  • Société Francophone du Diabète
  • Association Diabète Risque Vasculaire
  • Medical Research Council (MC_PC_13090)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, microangiopathy, macroangiopathy, major adverse cardiovascular events, all-cause mortality, cardiovascular risk stratification, ADVANCE trial, cardiovascular risk prediction models, diabetes complications, microvascular complications, macrovascular complications
MeSH terms
Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Combinations, Female, Gliclazide, Humans, Hypoglycemic Agents, Indapamide, Male, Middle Aged, Risk Factors, Treatment Outcome, Perindopril, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1186/s12933-017-0574-y
The paper
Mohammedi, K., Woodward, M., Marre, M., Colagiuri, S., Cooper, M., Harrap, S., Mancia, G., Poulter, N., Williams, B., Zoungas, S., & Chalmers, J. (2017). Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-017-0574-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.